- Basic Research
- Role of Intestinal Microbiota in Metabolism of Voglibose In Vitro and In Vivo
-
Mahesh Raj Nepal, Mi Jeong Kang, Geon Ho Kim, Dong Ho Cha, Ju-Hyun Kim, Tae Cheon Jeong
-
Diabetes Metab J. 2020;44(6):908-918. Published online April 6, 2020
-
DOI: https://doi.org/10.4093/dmj.2019.0147
-
-
6,346
View
-
127
Download
-
6
Web of Science
-
6
Crossref
-
 Abstract
 PDF Supplementary Material PubReader  ePub
-
Background
Voglibose, an α-glucosidase inhibitor, inhibits breakdown of complex carbohydrates into simple sugar units in intestine. Studies showed that voglibose metabolism in the liver might be negligible due to its poor intestinal absorption. Numerous microorganisms live in intestine and have several roles in metabolism and detoxification of various xenobiotics. Due to the limited information, the possible metabolism of voglibose by intestinal microbiota was investigated in vitro and in vivo.
Methods
For the in vitro study, different concentrations of voglibose were incubated with intestinal contents, prepared from both vehicle- and antibiotics-treated mice, to determine the decreased amount of voglibose over time by using liquid chromatography-mass spectrometry. Similarly, in vivo pharmacodynamic effect of voglibose was determined following the administration of voglibose and starch in vehicle- and antibiotic-pretreated non-diabetic and diabetic mice, by measuring the modulatory effects of voglibose on blood glucose levels.
Results
The in vitro results indicated that the remaining voglibose could be significantly decreased when incubated with the intestinal contents from normal mice compared to those from antibiotic-treated mice, which had less enzyme activities. The in vivo results showed that the antibiotic pretreatment resulted in reduced metabolism of voglibose. This significantly lowered blood glucose levels in antibiotic-pretreated mice compared to the control animals.
Conclusion
The present results indicate that voglibose would be metabolized by the intestinal microbiota, and that this metabolism might be pharmacodynamically critical in lowering blood glucose levels in mice.
-
Citations
Citations to this article as recorded by  - Pharmacomicrobiomics and type 2 diabetes mellitus: A novel perspective towards possible treatment
Liyang Jia, Shiqiong Huang, Boyu Sun, Yongguang Shang, Chunsheng Zhu
Frontiers in Endocrinology.2023;[Epub] CrossRef - Phenolics from endophytic fungi as natural α-glucosidase inhibitors: A comprehensive review
Muhammad Imran Tousif, Saba Tauseef, Sadeer Nabeelah, Jugreet Sharmeen, Gokhan Zengin, Lesetja Legoabe, Muhammad Imran, Mohamad Fawzi Mahomoodally
Journal of Molecular Structure.2023; 1291: 135852. CrossRef - Ligand-targeted fishing of α-glucosidase inhibitors from Tribulus terrestris L. based on chitosan-functionalized multi-walled carbon nanotubes with immobilized α-glucosidase
Xin Meng, Hou Zong, Zhong Zheng, Junpeng Xing, Zhiqiang Liu, Fengrui Song, Shu Liu
Analytical and Bioanalytical Chemistry.2023; 415(14): 2677. CrossRef - Isolation, structure elucidation, and biological activities of sesquiterpenes and phthalides from two edible mushrooms Pleurotus species
Jewel C De Padua, Emi Fukushima-Sakuno, Kotomi Ueno, Thomas Edison E dela Cruz, Atsushi Ishihara
Bioscience, Biotechnology, and Biochemistry.2023; 87(12): 1429. CrossRef - Effects of Oral Glucose-Lowering Agents on Gut Microbiota and Microbial Metabolites
Dongmei Wang, Jieying Liu, Liyuan Zhou, Qian Zhang, Ming Li, Xinhua Xiao
Frontiers in Endocrinology.2022;[Epub] CrossRef - 18:0 Lyso PC, a natural product with potential PPAR-γ agonistic activity, plays hypoglycemic effect with lower liver toxicity and cardiotoxicity in db/db mice
Yiming Ma, Xinyi Du, Dandan Zhao, Kegong Tang, Xiaona Wang, Shaoting Guo, Xiaobei Li, Song Mei, Na Sun, Jiaqi Liu, Chengyu Jiang
Biochemical and Biophysical Research Communications.2021; 579: 168. CrossRef
|
KDA
